NEWPORT BEACH, Calif.--(BUSINESS WIRE)--June 26, 2006--Acacia Research Corporation (Nasdaq:CBMX - News; Nasdaq:ACTG - News) announced today that its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics (CMDX) is planning to commercially launch its first molecular diagnostic service offering in August, 2006. This first product offering, which is already being sold in Europe through CMDX' distributor Array Genomics, is in the final phases of internal human/clinical validation prior to U.S. launch. This service utilizes CMDX' Constitutional Genetic Array Test (CGAT), which can genetically identify over 50 common genetic disorders in one test.
